Link Healthcare Japan
Employee ：Total 4 people + 1 CEO
About Link Healthcare Japan
Link Healthcare is dedicated to reducing unmet patient need by providing access to medicines and medical devices in Japan.
The healthcare system in Japan is highly regarded around the world. However, access to innovative, unapproved medicines, medical devices and off-label use of medicines are limited compared with European countries and the US. For sound clinical reasons and to ensure patients with unmet need have access to the most appropriate treatment, healthcare professionals in Japan need access to unlicensed medicines. We support the doctors’ private import required throughout the process, from examination of products to supply including pharmaceutical application, paperwork for import, and logistics.
We source and supply medicines and medical devices from European countries and the US, using our local market knowledge and global expertise to ensure ethical, compliant and timely access for healthcare professionals through “Named Patient Supply” and early access through “Managed Access Programmes”.
For over 10 years, Link Healthcare has been the market leader in providing healthcare professionals in Japan with access to unlicensed medicines and medical devices.
Link Healthcare became part of the Clinigen Group in 2015, significantly strengthening the Group’s global presence and position in the AAA region and enabling Link Healthcare Japan to further establish its global network.
Link Healthcare supplies medicines and medical devices to national and public university hospitals, private university hospitals, national hospitals and clinics; working with almost 5,000 healthcare professional across over 3,500 sites by the end of July 2017. Link Healthcare provides access to a broad range of therapeutic areas including; supporting national organizations, we have provided vaccines for rabies, typhoid and meningitis to Ministry of Defense and the influenza vaccine to the Japan Football Association in 2010 FIFA World Cup.
Employee ：Total 9 people + 1 (CEO Japan branch)
About Clinigen K.K.
The Japanese business allows the Group to supply and distribute both licensed and unlicensed medicines in Japan providing additional infrastructure to support Clinigen's mission to deliver the right medicine to the right patient at the right time. We understand the needs of the market and are expanding the therapeutic areas we can support with, focusing on the fields of rare disease and oncology. We are dedicated to providing healthcare professionals with the solutions they need.
In April 2016, Clinigen Group plc launched a wholly-owned subsidiary, Clinigen K.K., further explanding the Group’s presence in Asia. Clinigen K.K. gained the Marketing Authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir® (foscarnet sodium).